Cascadian Therapeutics (CASC)

[aries4747]

Oncothyreon (NASDAQ:ONTY) Short Interest Increased By 4.33%

http://www.smallcapwired.com/oncothyreon-nasdaqonty-short-interest-increased-by-4-33/69189/

By Linda Rogers on March 4, 2016 Stock News

The stock of Oncothyreon (NASDAQ:ONTY) registered an increase of 4.33% in short interest. ONTY’s total short interest was 7.44M shares in March as published by FINRA. Its up 4.33% from 7.13M shares, reported previously. With 682,200 shares average volume, it will take short sellers 11 days to cover their ONTY’s short positions. The short interest to Oncothyreon’s float is 10.4%. The stock increased 4.31% or $0.05 during the last trading session, hitting $1.21. About 977,808 shares traded hands or 27.66% up from the average. Oncothyreon Inc (USA) (NASDAQ:ONTY) has declined 67.23% since July 29, 2015 and is downtrending. It has underperformed by 62.13% the S&P500.

Oncothyreon Inc. is a clinical-stage biopharmaceutical firm focused primarily on the development of therapeutic products for the treatment of cancer. The company has a market cap of $124.52 million. The Company’s clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. It currently has negative earnings. The Firm is developing preclinical product candidates in oncology, and certain rare diseases, using its protocell technology.

The institutional sentiment decreased to 0.47 in 2015 Q3. Its down 1.17, from 1.64 in 2015Q2. The ratio worsened, as 22 funds sold all Oncothyreon Inc (USA) shares owned while 42 reduced positions. 9 funds bought stakes while 21 increased positions. They now own 55.19 million shares or 1.99% less from 56.32 million shares in 2015Q2.

Bvf Inc Il holds 9.06% of its portfolio in Oncothyreon Inc (USA) for 16.36 million shares. Venbio Select Advisor Llc owns 5.51 million shares or 3.92% of their US portfolio. Moreover, Perkins Capital Management Inc has 1.19% invested in the company for 390,650 shares. The California-based Ecor1 Capital Llc has invested 1.18% in the stock. Redmile Group Llc, a California-based fund reported 3.61 million shares.

Out of 4 analysts covering Oncothyreon (NASDAQ:ONTY), 4 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Oncothyreon was the topic in 5 analyst reports since August 7, 2015 according to StockzIntelligence Inc.